Merrimack Pharmaceuticals Inc. Initiates Phase 2 Clinical Study of MM-111 in Advanced Gastroesophageal Cancers

Published: Jul 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news